Printer Friendly

Zila's OraTest to be Sold in Hungary and Elsewhere.

PHOENIX--(BUSINESS WIRE)--Nov. 25, 1996--Zila, Inc. (NASDAQ: ZILA), international marketer of oral healthcare products, announced that OraTest, the first oral cancer detection system, has been approved for sale by regulators in Hungary, providing Zila with its first Eastern European market.

Zila President Joseph Hines said, "While Hungary is a nation of only 10.3 million people, OraTest will play an important role there." The American Cancer Society's ranking of 48 countries places Hungary No. 1 in per-capita oral cancer incidence. Zila is finalizing a distribution agreement with Hungary's premier dental products distributor. Product will be produced in the U.K. by Zila's contract manufacturer there. The first shipment to Hungary is scheduled for January; sales should commence immediately thereafter.

Hines said considerable progress has been made toward obtaining regulatory approvals and distribution agreements in other international markets as well. OraTest sales are expected to begin in Poland in the Spring. Bermuda has approved OraTest; a sales agreement is being prepared that will cover that country and several additional Caribbean island nations. A firm order has been received from India, where oral cancer is the No. 1 cause of cancer-related deaths. As soon as logistics can be arranged, OraTest will be shipped for use at major cancer centers there.

OraTest is already in use in Canada, the United Kingdom and Australia. U.S. FDA approval is pending.

Zila has signed a definitive agreement to acquire Bio-Dental Technologies Corporation -- a move that will increase Zila's annual revenue from $6.8 million (reported in FY 1996) to an estimated $40.0 million in FY 1997.

The information set forth in this press release includes forward-looking statements and references to potential future developments. Such statements and references are based upon certain assumptions, including, but not limited to, the closing of Zila's acquisition of Bio-Dental and FDA approval of OraTest.

CONTACT: Zila, Inc.

Joe Hines, 602/266-6700
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 25, 1996
Words:313
Previous Article:Zila Hires Brad Anderson as Vice President - Treasurer.
Next Article:Equipe Launches New Software for Increased Throughput.
Topics:


Related Articles
Zila completes acquisition of CTM Associates.
Zila Reports Record FY 1996 Sales and Revenue.
Zila Hires Brad Anderson as Vice President - Treasurer.
Zila to market OraTest in Republic of China.
Zila Acquires Oxycal Laboratories.
Zila's OraTest Oral Cancer Detection System Approved in Several European Union Nations.
Zila Gets Additional U.S. Patent for Zila Tolonium Chloride Technology.
Zila Appoints Dr. Douglas D. Burkett President & CEO; Joseph Hines Continues as Chairman.
Zila Reports Third Quarter Results.
Zila Receives $4 Million for Sale of Remaining Dental Supply Operations.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters